Novo Nordisk's Main Europe Problem Is Reimbursement

Novo Nordisk's Main Europe Problem Is Reimbursement Play

May 1 (Bloomberg) -- Jesper Brandgaard, chief financial officer of Novo Nordisk A/S, discusses its Tresiba diabetes treatment, European Medicines Agency concerns about its diabetes treatment Victoza and challenges in the European market. He speaks from Copenhagen with Francine Lacqua and Caroline Hyde on Bloomberg Television's "On the Move." (Source: Bloomberg)

  • On Air Now

    Bloomberg West Watch Now

  • Next

    PAID PROGRAMMING

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus